Communiqués de presse Archive - Page 20 of 24 - Ose Immunotherapeutics - Société de biotechnologie intégrée qui développe des immunothérapies innovantes

OSE Immunotherapeutics Receives €200,000 from Nantes Metropole to Develop CoVepiT

OSE Immunotherapeutics Announces Results of 2020 Virtual Combined General Meeting

OSE Immunotherapeutics Presents New Data Supporting Bispecific Antibody Checkpoint Inhibitor Platform

OSE Immunotherapeutics Identifies Monoclonal Antibody Antagonists of CLEC-1

OSE Immunotherapeutics Signs €7 Million Non-Dilutive Loan Agreement Guaranteed by the French State

OSE Immunotherapeutics Announces Procedures for Virtual Combined General Meeting

OSE Immunotherapeutics Presents CLEC-1

OSE Immunotherapeutics Announces COVID-19 Prophylactic Vaccine Program

OSE Immunotherapeutics Announces Positive Top-Line Results for Step-1 of its trial ‘Atalante 1’

OSE Immunotherapeutics Reports 2019 Financial Results

Précédent
1
…
17
18
19
20
21
22
23
24
Suivant